JP Morgan Maintains Overweight on GoodRx Holdings, Lowers Price Target to $5
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
JP Morgan analyst Lisa Gill maintains GoodRx Holdings (NASDAQ:GDRX) with a Overweight and lowers the price target from $6 to $5.
JP Morgan analyst Lisa Gill maintains GoodRx Holdings (NASDAQ:GDRX) with a Overweight and lowers the price target from $6 to $5.